Ghassan K. Abou-Alfa, MD, MBA, reviews key clinical trial data and treatment options for the management of unresectable HCC.
EP. 1: Case Overview: 68-Year-Old Man With Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD, MBA, presents the case of a 68-year-old man with hepatocellular carcinoma (HCC) and shares his initial impressions.
EP. 2: Frontline Treatment Options for Unresectable HCC
An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.
EP. 3: Phase 3 REFLECT Trial in Unresectable HCC
Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.
EP. 4: Future of Unresectable HCC Management
Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.
EP. 5: Key Takeaways for the Treatment of Unresectable HCC
Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.
2 Clarke Drive Cranbury, NJ 08512